18FET-PET Predicts Survival Benefit From Bevacizumab Plus Radiotherapy in Patients With IDH Wild-Type Glioblastoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
MRI and 18FET-PET Predict Survival Benefit From Bevacizumab Plus Radiotherapy in Patients With IDH Wild-Type Glioblastoma: Results From the Randomized ARTE Trial
Clin. Cancer Res 2020 Sep 23;[EPub Ahead of Print], HG Wirsching, U Roelcke, J Weller, T Hundsberger, AF Hottinger, R von Moos, F Caparrotti, K Conen, L Remonda, P Roth, AF Ochsenbein, G Tabatabai, M WellerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.